Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Spyre tumbles as immune drug misses mark in rheumatoid arthritis

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 26 August →